ClinicalTrials.Veeva

Menu

Effects of Protein and NAC Co-ingestion on Skeletal Muscle Recovery (PRoNAC)

U

University of Thessaly

Status

Enrolling

Conditions

Aseptic Muscle Injury

Treatments

Dietary Supplement: NAC
Dietary Supplement: Placebo
Dietary Supplement: NAC + Whey Protein

Study type

Interventional

Funder types

Other

Identifiers

NCT06367413
UTH-PRoNAC Study

Details and patient eligibility

About

Previous evidence suggests that though N-acetylcysteine (NAC) supplementation following eccentric exercise-induced muscle damage disrupts the skeletal muscle's repair and remodelling process at 8 days of recovery, it attenuates substantially the decline of skeletal muscle performance during the first 48 hours of recovery. The enhanced performance capacity during the first phase of recovery in response to NAC supplementation might be attributed to the altered redox status in skeletal muscle as a consequence of the NAC-mediated elevation of reduced glutathione (GSH) levels. The rise in GSH results in a redox-dependent attenuation of immune cell mobilisation and reduction of oxidative stress response, leading to a blunted rise of muscle damage and inflammatory markers during the first 2-3 days of recovery. However, following exercise-induced muscle damage, protein synthesis increases in skeletal muscle over the next 24-48 hours to support its repair process, and thus protein supplementation might accelerate the recovery process by enhancing the protein synthetic response. Therefore, the present study aims at investigating for first time the combined effect of NAC and whey protein supplementation on the short-term (during the first 72 hours) recovery process of skeletal muscle following damaging exercise (eccentric exercise) and compared it with the well-documented efficacy of NAC supplementation. The results of this study might be particularly useful for athletes, such as those in soccer and basketball, that participate in 3 games or intense training sessions during the same macrocycle with only 48-72 hours of recovery in-between.

Full description

Participants will initially undergo baseline testing including assessment of their (i) anthropometrics, (ii) body composition via DXA, (iii) habitual physical activity level via accelerometry, (iv) resting metabolic rate via indirect calorimetry, (v) daily dietary intake via 7-day dietary recalls and (vi) cardiorespiratory fitness using a treadmill ramp test. After baseline testing, participants will be assigned to (a) a Placebo, (b) a N-acetylcysteine (NAC) or (c) a N-acetylcysteine + Whey protein (PRoNAC) group, in a randomized, double-blind, placebo-controlled, parallel group, repeated measures design. In all groups, participants will execute an eccentric exercise protocol on an isokinetic dynamometer consisted of 150 eccentric muscle contractions. Before exercise as well as at 1-, 2-, 3-, 24-, 48- and 72-hours post-exercise they will undergo assessment of their maximal voluntary isometric peal torque, maximal countermovement jump height and muscle soreness level. In addition, blood sample will be drawn before exercise and at 24-, 48- and 72-hours post-exercise for the determination of myoglobin concentration, reduced (GSH) and oxidized (GSSG) glutathione content, protein carbonyl formation and catalase activity.

Throughout the 4-day experimental period (Day 1: exercise day, Days 2, 3 and 4: 24-, 48- and 72-hours post-exercise, respectively) participants will receive daily, 3 doses from the respective supplement as follows: the 1st dose at mid-morning (between breakfast and lunch), the 2nd dose at mid-afternoon (post-exercise on day 1 and between lunch and dinner on days 2-4) and the 3rd dose before sleep. In Placebo group, participants will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day). In NAC group, participants will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day). In PRoNAC group participants will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).

Enrollment

30 estimated patients

Sex

Male

Ages

18 to 27 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Free of asthma, kidney disease, bleeding disorders, peptic ulcers.
  • Free of musculoskeletal injuries and limitations.
  • Abstain from dietary energy restriction.
  • Do not use medication such as anti-inflammatory drugs, antibiotics, antihypertensive drugs or anticoagulants.
  • Do not use dietary supplements such as protein, carbohydrate, antioxidants, vitamins etc.
  • Free of N-acetylcysteine intolerance.
  • Non-smokers.
  • Abstain from alcohol throughout the study.

Exclusion criteria

  • Presence of asthma, kidney disease, bleeding disorders, peptic ulcers.
  • Musculoskeletal injuries and limitations.
  • Dietary energy restriction.
  • Use of anti-inflammatory drugs, antibiotics, antihypertensive drugs or anticoagulants.
  • Use of dietary supplements such as protein, carbohydrate, antioxidants, vitamins etc.
  • N-acetylcysteine intolerance.
  • Smoking.
  • Alcohol consumption during the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

30 participants in 3 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Participants in this arm will execute 150 eccentric muscle contractions an receive a placebo supplement consisted of carbohydrate (maltodextrin).
Treatment:
Dietary Supplement: Placebo
NAC
Experimental group
Description:
Participants in this arm will execute 150 eccentric muscle contractions an receive a N-acetylcysteine supplement.
Treatment:
Dietary Supplement: NAC
PRoNAC
Experimental group
Description:
Participants in this arm will execute 150 eccentric muscle contractions an receive a supplement consisted of N-acetylcysteine and whey protein.
Treatment:
Dietary Supplement: NAC + Whey Protein

Trial contacts and locations

1

Loading...

Central trial contact

Dimitrios Draganidis, PhD; Ioannis G Fatouros, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems